Trial · NCT03242018
Adverse events258
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
121 to 140 of 258
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Diastolic dysfunction | Cardiac disorders | Placebo | 0 | 93 | |
| serious | Diastolic dysfunction | Cardiac disorders | Sotagliflozin 200 mg | 0 | 94 | |
| serious | Diastolic dysfunction | Cardiac disorders | Sotagliflozin 400 mg | 1 | 90 | |
| serious | Myocardial infarction | Cardiac disorders | Placebo | 0 | 93 | |
| serious | Myocardial infarction | Cardiac disorders | Sotagliflozin 200 mg | 0 | 94 | |
| serious | Myocardial infarction | Cardiac disorders | Sotagliflozin 400 mg | 1 | 90 | |
| serious | Acute respiratory failure | Respiratory, thoracic and mediastinal disorders | Placebo | 1 | 93 | |
| serious | Acute respiratory failure | Respiratory, thoracic and mediastinal disorders | Sotagliflozin 200 mg | 1 | 94 | |
| serious | Acute respiratory failure | Respiratory, thoracic and mediastinal disorders | Sotagliflozin 400 mg | 1 | 90 | |
| serious | Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | Placebo | 1 | 93 | |
| serious | Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | Sotagliflozin 200 mg | 0 | 94 | |
| serious | Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders | Sotagliflozin 400 mg | 1 | 90 | |
| serious | Chronic respiratory failure | Respiratory, thoracic and mediastinal disorders | Placebo | 1 | 93 | |
| serious | Chronic respiratory failure | Respiratory, thoracic and mediastinal disorders | Sotagliflozin 200 mg | 0 | 94 | |
| serious | Chronic respiratory failure | Respiratory, thoracic and mediastinal disorders | Sotagliflozin 400 mg | 0 | 90 | |
| serious | Painful respiration | Respiratory, thoracic and mediastinal disorders | Placebo | 0 | 93 | |
| serious | Painful respiration | Respiratory, thoracic and mediastinal disorders | Sotagliflozin 200 mg | 0 | 94 | |
| serious | Painful respiration | Respiratory, thoracic and mediastinal disorders | Sotagliflozin 400 mg | 1 | 90 | |
| serious | Pulmonary congestion | Respiratory, thoracic and mediastinal disorders | Placebo | 0 | 93 | |
| serious | Pulmonary congestion | Respiratory, thoracic and mediastinal disorders | Sotagliflozin 200 mg | 0 | 94 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03242018/events?page=7